TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07550842: An Open, Multi-center Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Ce

Sponsor: Shanghai Best-Link Bioscience, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 33 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,298,680

Rescue Site Savings

+$2,167,704

Unlock Full NCT07550842 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07550842 Rescue Dossier →